Pa. Transit Agency Slaps Gilead With Price-Gouging Suit

Law360, New York (December 11, 2014, 5:38 PM ET) -- A Pennsylvania transportation agency has hit Gilead Sciences Inc. with a class action over its hepatitis C drug Sovaldi, claiming that the pharmaceutical giant is maintaining a questionable monopoly on the medicine and price-gouging customers for it, as well as running afoul of the Affordable Care Act.



The Southeastern Pennsylvania Transportation Authority alleges in its suit filed Tuesday that Gilead is engaging in unjust enrichment by charging exorbitant prices for Sovaldi, for which a standard three-month regimen costs $84,000, or $1,000 per pill, according to the...

To view the full article, register now.